AI Powered Lyme Diagnostics:

The Future is Multiplexed

Join James Needham, Ph.D, Director of Product Development, for

AI-Powered Lyme Diagnostics: The Future is Multiplexed

ADLM Annual Meeting
McCormick Place Convention Center, Chicago, IL
Exhibit Hall Theater #3
Tuesday, July 29th, 11:30 – 11:50 a.m.

Sign Up for Updates

You’ll get a first look at InBios’ novel array-based immunoassay in an ELISA plate format that significantly improves workflow and acute stage sensitivity for the diagnosis of Lyme disease. While you’re at ADLM, stop by and visit InBios reps at Booth #1137.

InBios International, Inc has developed the Lyme Detect™ Multiplex ELISA. In a single immunoassay, IgG and IgM antibodies targeting a wide panel of B. Burgdorferi target antigens are simultaneously quantified and automatically analyzed to determine status of the clinical specimen. Controls for each well are included to determine the relative amount of human IgG and IgM present in each unique sample and to verify the test was run properly. Here, we present pre-clinical testing and in-house performance data and compare it to the standard two-tier testing (STTT) algorithm. Initial testing with blinded specimens indicates a statistically significant 30-40% sensitivity improvement for detecting early Lyme-EM specimens when compared to STTT. Specificity is not compromised with minimal to no cross-reactivity observed with problematic samples, including rheumatoid factor (RF) positive samples.